Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Statins to Prevent Immune Checkpoint Inhibitor-induced Progression of Atherosclerosis (SPIRAL)
2024-511127-33-00Phase 4Authorised
- Sponsor
- Erasmus MC
- Start
- May 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, double-blind trial in atherosclerosis comparing atorvastatin arm with placebo arm (2 arms). Primary endpoint: Annualized percentage change in non-calcified atherosclerotic plaque volume in the thoracic aorta. Planned start May 2025; status: authorised.
02
Drugs
atorvastatin
03
Conditions
atherosclerosis
Beyond the preview
Go deeper on 2024-511127-33-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-511127-33-00.